Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Topical corticosteroids may indirectly provide relief of itch associated with inflammatory skin diseases such as atopic dermatitis, but they should not be used to treat generalized itch.

Therefore, even individuals without childhood eczema may experience it later in life. Dr Grant has debunked the common ...

The phase 3 INTEGUMENT programme also found that the drug achieved a significant reduction in itch, the most ... have been the foundation of treatment for atopic dermatitis for the past 50 years ...

Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching ... is especially promising in treatment of this disease. Having been in ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.